Ratings by Wells Fargo (Mohit Bansal)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/25/2026 | Jazz Pharmaceuticals | JAZZ | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/19/2026 | Halozyme Therapeutics | HALO | Maintain | Equal Weight (N/A) |
|
Details | ||
| 2/19/2026 | Amgen | AMGN | Maintain | Equal Weight (N/A) |
|
Details | ||
| 2/13/2026 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/11/2026 | Gilead Sciences | GILD | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/9/2026 | Biogen | BIIB | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 2/6/2026 | Bristol-Myers Squibb Co. | BMY | Maintain | Equal Weight (N/A) |
|
Details | ||
| 2/5/2026 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 2/5/2026 | Eli Lilly | LLY | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/4/2026 | Merck | MRK | Maintain | Overweight (N/A) |
|
Details | ||
| 2/2/2026 | Regeneron Pharma | REGN | Maintain | Equal Weight (N/A) |
|
Details | ||
| 1/5/2026 | Ironwood Pharmaceuticals | IRWD | Maintain | Equal Weight (N/A) |
|
Details | ||
| 12/16/2025 | Milestone Pharmaceuticals | MIST | Maintain | Overweight (Overweight) |
|
Details | ||
| 12/10/2025 | Bristol-Myers Squibb Co. | BMY | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 12/10/2025 | Eli Lilly | LLY | Maintain | Overweight (Overweight) |
|
Details | ||
| 12/10/2025 | Vertex | VRTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 12/10/2025 | Regeneron Pharma | REGN | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 12/10/2025 | Gilead Sciences | GILD | Maintain | Overweight (Overweight) |
|
Details | ||
| 12/10/2025 | Biogen | BIIB | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 12/10/2025 | Amgen | AMGN | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 11/24/2025 | Merck | MRK | Upgrade | Overweight (Equal Weight) |
97.76 (115.79) |
18.44% | Details | |
| 11/20/2025 | Regeneron Pharma | REGN | Maintain | Equal Weight (N/A) |
|
Details | ||
| 11/18/2025 | Jazz Pharmaceuticals | JAZZ | Maintain | Overweight (N/A) |
|
Details | ||
| 11/11/2025 | Ironwood Pharmaceuticals | IRWD | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 11/5/2025 | Amgen | AMGN | Maintain | Equal Weight (N/A) |
|
Details | ||
| 10/31/2025 | Gilead Sciences | GILD | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/31/2025 | Biogen | BIIB | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 10/29/2025 | Regeneron Pharma | REGN | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 9/12/2025 | Abbvie | ABBV | Maintain | Overweight (Overweight) |
|
Details | ||
| 9/11/2025 | Travere Therapeutics | TVTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 9/11/2025 | Milestone Pharmaceuticals | MIST | New Coverage | Overweight (N/A) |
1.71 (1.58) |
-7.6% | Details | |
| 8/6/2025 | Vertex | VRTX | Upgrade | Overweight (Equal Weight) |
374.98 (456.69) |
21.79% | Details | |
| 8/5/2025 | BioNTech | BNTX | Maintain | Overweight (N/A) |
|
Details | ||
| 7/30/2025 | Merck | MRK | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 5/30/2025 | Regeneron Pharma | REGN | Downgrade | Equal Weight (Overweight) |
605.39 (759.86) |
25.52% | Details | |
| 5/13/2025 | Xenon Pharmaceuticals | XENE | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/7/2025 | Halozyme Therapeutics | HALO | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 4/30/2025 | Regeneron Pharma | REGN | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/28/2025 | Bristol-Myers Squibb Co. | BMY | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 4/23/2025 | Regeneron Pharma | REGN | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/14/2025 | Ironwood Pharmaceuticals | IRWD | Downgrade | Equal Weight (Overweight) |
0.95 (3.50) |
268.42% | Details | |
| 4/1/2025 | Eli Lilly | LLY | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/5/2025 | Eli Lilly | LLY | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/5/2025 | Gilead Sciences | GILD | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/5/2025 | Abbvie | ABBV | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/28/2025 | Xenon Pharmaceuticals | XENE | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/13/2025 | Jazz Pharmaceuticals | JAZZ | Maintain | Overweight (N/A) |
|
Details | ||
| 2/13/2025 | Biogen | BIIB | Maintain | Equal Weight (N/A) |
|
Details | ||
| 2/12/2025 | Gilead Sciences | GILD | Maintain | Overweight (N/A) |
|
Details | ||
| 2/7/2025 | Bristol-Myers Squibb Co. | BMY | Maintain | Equal Weight (N/A) |
|
Details | ||
| 2/5/2025 | Merck | MRK | Maintain | Equal Weight (N/A) |
|
Details | ||
| 2/3/2025 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 1/31/2025 | Ironwood Pharmaceuticals | IRWD | Maintain | Overweight (N/A) |
|
Details | ||
| 1/30/2025 | Vertex | VRTX | Downgrade | Equal Weight (Overweight) |
441.52 (456.69) |
3.44% | Details | |
| 1/28/2025 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 1/15/2025 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 11/8/2024 | Jazz Pharmaceuticals | JAZZ | Maintain | Equal Weight (N/A) |
|
Details | ||
| 11/7/2024 | Gilead Sciences | GILD | Maintain | Overweight (N/A) |
|
Details | ||
| 11/1/2024 | Merck | MRK | Maintain | Equal Weight (N/A) |
|
Details | ||
| 10/31/2024 | Biogen | BIIB | Maintain | Equal Weight (N/A) |
|
Details | ||
| 10/23/2024 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/21/2024 | Travere Therapeutics | TVTX | Upgrade | Overweight (Equal Weight) |
17.87 (27.24) |
52.43% | Details | |
| 10/10/2024 | Travere Therapeutics | TVTX | Maintain | Equal Weight (N/A) |
|
Details | ||
| 10/10/2024 | Gilead Sciences | GILD | Maintain | Overweight (N/A) |
|
Details | ||
| 10/7/2024 | Halozyme Therapeutics | HALO | Downgrade | Equal Weight (Overweight) |
59.18 (67.37) |
13.84% | Details | |
| 10/7/2024 | Gilead Sciences | GILD | Upgrade | Overweight (Equal Weight) |
84.59 (143.93) |
70.15% | Details | |
| 8/20/2024 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 8/9/2024 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 8/7/2024 | Amgen | AMGN | Downgrade | Equal Weight (Overweight) |
325.22 (369.53) |
13.62% | Details | |
| 8/2/2024 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 8/2/2024 | Biogen | BIIB | Maintain | Equal Weight (N/A) |
|
Details | ||
| 8/1/2024 | Jazz Pharmaceuticals | JAZZ | Maintain | Equal Weight (N/A) |
|
Details | ||
| 7/31/2024 | Pfizer | PFE | Maintain | Equal Weight (N/A) |
|
Details | ||
| 7/31/2024 | Merck | MRK | Maintain | Equal Weight (N/A) |
|
Details | ||
| 7/26/2024 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 6/24/2024 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
| 6/12/2024 | Merck | MRK | Maintain | Equal Weight (N/A) |
|
Details | ||
| 6/7/2024 | Halozyme Therapeutics | HALO | Maintain | Overweight (N/A) |
|
Details | ||
| 6/5/2024 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/22/2024 | Ironwood Pharmaceuticals | IRWD | Maintain | Overweight (N/A) |
|
Details | ||
| 5/22/2024 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
| 5/16/2024 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 5/1/2024 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 4/26/2024 | Merck | MRK | Maintain | Equal Weight (N/A) |
|
Details | ||
| 4/24/2024 | Neurocrine Bio. | NBIX | Upgrade | Overweight (Equal Weight) |
133.66 (128.13) |
-4.14% | Details | |
| 4/17/2024 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
| 3/27/2024 | Merck | MRK | Maintain | Equal Weight (N/A) |
|
Details | ||
| 3/4/2024 | Gilead Sciences | GILD | Maintain | Equal Weight (N/A) |
|
Details | ||
| 3/1/2024 | Ironwood Pharmaceuticals | IRWD | Maintain | Overweight (N/A) |
|
Details | ||
| 3/1/2024 | Xenon Pharmaceuticals | XENE | Maintain | Overweight (N/A) |
|
Details | ||
| 2/16/2024 | Travere Therapeutics | TVTX | Maintain | Equal Weight (N/A) |
|
Details | ||
| 2/14/2024 | Biogen | BIIB | Downgrade | Equal Weight (Overweight) |
226.65 (184.87) |
-18.43% | Details | |
| 2/8/2024 | Neurocrine Bio. | NBIX | Maintain | Equal Weight (N/A) |
|
Details | ||
| 2/7/2024 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 2/7/2024 | Gilead Sciences | GILD | Maintain | Equal Weight (N/A) |
|
Details | ||
| 2/2/2024 | Merck | MRK | Maintain | Equal Weight (N/A) |
|
Details | ||
| 1/24/2024 | Merck | MRK | Maintain | Equal Weight (N/A) |
|
Details | ||
| 1/24/2024 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 1/18/2024 | Halozyme Therapeutics | HALO | Maintain | Overweight (N/A) |
|
Details | ||
| 1/3/2024 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 12/26/2023 | Karuna Therapeutics Inc. | KRTX | Downgrade | Equal Weight (Overweight) |
215.19 (329.83) |
53.27% | Details | |
| 12/14/2023 | Pfizer | PFE | Maintain | Equal Weight (N/A) |
|
Details | ||
| 12/14/2023 | Vertex | VRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 12/14/2023 | Ironwood Pharmaceuticals | IRWD | New Coverage | Overweight (N/A) |
10.69 (3.50) |
-67.26% | Details | |
| 12/13/2023 | Neurocrine Bio. | NBIX | Maintain | Equal Weight (N/A) |
|
Details | ||
| 11/9/2023 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
| 10/30/2023 | Bristol-Myers Squibb Co. | BMY | Maintain | Equal Weight (N/A) |
|
Details | ||
| 10/27/2023 | Bristol-Myers Squibb Co. | BMY | Maintain | Equal Weight (N/A) |
|
Details | ||
| 10/16/2023 | Pfizer | PFE | Maintain | Equal Weight (N/A) |
|
Details | ||
| 10/12/2023 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/9/2023 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 8/21/2023 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 8/10/2023 | Halozyme Therapeutics | HALO | Maintain | Overweight (N/A) |
|
Details | ||
| 8/7/2023 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
| 8/3/2023 | Pfizer | PFE | Maintain | Equal Weight (N/A) |
|
Details | ||
| 8/1/2023 | Chinook Therapeutics | KDNY | Downgrade | Equal Weight (Overweight) |
39.08 (40.39) |
3.35% | Details | |
| 7/28/2023 | Bristol-Myers Squibb Co. | BMY | Maintain | Equal Weight (N/A) |
|
Details | ||
| 6/28/2023 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 6/12/2023 | Jazz Pharmaceuticals | JAZZ | New Coverage | Equal Weight (N/A) |
127.10 (182.01) |
43.2% | Details | |
| 5/26/2023 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 5/4/2023 | Neurocrine Bio. | NBIX | Maintain | Equal Weight (N/A) |
|
Details | ||
| 5/4/2023 | Cerevel Therapeutics | CERE | Upgrade | Overweight (Equal Weight) |
30.90 (44.96) |
45.5% | Details | |
| 4/28/2023 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 4/28/2023 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 4/14/2023 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 3/24/2023 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 3/24/2023 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 3/17/2023 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 3/17/2023 | Pfizer | PFE | Maintain | Equal Weight (N/A) |
|
Details | ||
| 3/16/2023 | Halozyme Therapeutics | HALO | Maintain | Overweight (N/A) |
|
Details | ||
| 3/13/2023 | Merck | MRK | Downgrade | Equal Weight (Overweight) |
107.69 (115.79) |
7.52% | Details | |
| 3/13/2023 | Eli Lilly | LLY | Upgrade | Overweight (Equal Weight) |
315.02 (990.33) |
214.37% | Details | |
| 3/13/2023 | Amgen | AMGN | Upgrade | Overweight (Equal Weight) |
227.87 (369.53) |
62.17% | Details | |
| 2/22/2023 | Cerevel Therapeutics | CERE | Downgrade | Equal Weight (Overweight) |
31.00 (44.96) |
45.03% | Details | |
| 2/21/2023 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 2/7/2023 | Neurocrine Bio. | NBIX | Maintain | Equal Weight (N/A) |
|
Details | ||
| 2/3/2023 | Merck | MRK | Maintain | Overweight (N/A) |
|
Details | ||
| 2/3/2023 | Eli Lilly | LLY | Maintain | Equal Weight (N/A) |
|
Details | ||
| 2/1/2023 | Amgen | AMGN | Maintain | Equal Weight (N/A) |
|
Details | ||
| 1/17/2023 | Pfizer | PFE | Downgrade | Equal Weight (Overweight) |
47.71 (27.05) |
-43.3% | Details | |
| 1/3/2023 | Merck | MRK | Maintain | Overweight (N/A) |
|
Details | ||
| 1/3/2023 | Bristol-Myers Squibb Co. | BMY | Maintain | Equal Weight (N/A) |
|
Details | ||
| 1/3/2023 | Gilead Sciences | GILD | Maintain | Equal Weight (N/A) |
|
Details | ||
| 1/3/2023 | Amgen | AMGN | Maintain | Equal Weight (N/A) |
|
Details | ||
| 12/8/2022 | Eli Lilly | LLY | Maintain | Equal Weight (N/A) |
|
Details | ||
| 11/28/2022 | Xenon Pharmaceuticals | XENE | New Coverage | Overweight (N/A) |
34.81 (38.71) |
11.2% | Details | |
| 11/28/2022 | Halozyme Therapeutics | HALO | New Coverage | Equal Weight (N/A) |
54.42 (67.37) |
23.8% | Details | |
| 11/2/2022 | Pfizer | PFE | Maintain | Overweight (N/A) |
|
Details | ||
| 11/2/2022 | Eli Lilly | LLY | Maintain | Equal Weight (N/A) |
|
Details | ||
| 11/2/2022 | Neurocrine Bio. | NBIX | Maintain | Equal Weight (N/A) |
|
Details | ||
| 10/28/2022 | Merck | MRK | Maintain | Overweight (N/A) |
|
Details | ||
| 10/28/2022 | Vertex | VRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/28/2022 | Gilead Sciences | GILD | Maintain | Equal Weight (N/A) |
|
Details | ||
| 9/28/2022 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
| 9/26/2022 | Neurocrine Bio. | NBIX | New Coverage | Equal Weight (N/A) |
103.50 (133.66) |
29.14% | Details | |
| 9/26/2022 | Cerevel Therapeutics | CERE | New Coverage | Overweight (N/A) |
26.21 (44.96) |
71.54% | Details | |
| 9/13/2022 | Gilead Sciences | GILD | Maintain | Equal Weight (N/A) |
|
Details | ||
| 9/12/2022 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 6/3/2022 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 5/17/2022 | Bristol-Myers Squibb Co. | BMY | Maintain | Equal Weight (N/A) |
|
Details | ||
| 5/6/2022 | Vertex | VRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/2/2022 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 4/29/2022 | Merck | MRK | Maintain | Overweight (N/A) |
|
Details | ||
| 4/29/2022 | Eli Lilly | LLY | Maintain | Equal Weight (N/A) |
|
Details | ||
| 4/18/2022 | Biogen | BIIB | Upgrade | Overweight (Equal Weight) |
212.55 (226.65) |
6.63% | Details | |
| 3/22/2022 | Gilead Sciences | GILD | Maintain | Equal Weight (N/A) |
|
Details | ||
| 3/2/2022 | Bristol-Myers Squibb Co. | BMY | Maintain | Equal Weight (N/A) |
|
Details | ||
| 2/9/2022 | Amgen | AMGN | Maintain | Equal Weight (N/A) |
|
Details | ||
| 2/4/2022 | Biogen | BIIB | Maintain | Equal Weight (N/A) |
|
Details | ||
| 2/2/2022 | Gilead Sciences | GILD | Maintain | Equal Weight (N/A) |
|
Details | ||
| 1/7/2022 | Pfizer | PFE | Maintain | Overweight (N/A) |
|
Details | ||
| 12/30/2021 | Biogen | BIIB | Maintain | Equal Weight (N/A) |
|
Details | ||
| 12/9/2021 | Biogen | BIIB | New Coverage | Equal Weight (N/A) |
226.83 (212.55) |
-6.3% | Details | |
| 12/9/2021 | Bristol-Myers Squibb Co. | BMY | New Coverage | Equal Weight (N/A) |
57.13 (60.29) |
5.53% | Details | |
| 12/9/2021 | Amgen | AMGN | New Coverage | Equal Weight (N/A) |
211.32 (369.53) |
74.87% | Details | |
| 12/9/2021 | Gilead Sciences | GILD | New Coverage | Equal Weight (N/A) |
69.65 (143.93) |
106.65% | Details | |
| 12/9/2021 | Eli Lilly | LLY | New Coverage | Equal Weight (N/A) |
245.11 (990.33) |
304.03% | Details | |
| 12/9/2021 | Regeneron Pharma | REGN | New Coverage | Overweight (N/A) |
635.09 (759.86) |
19.65% | Details | |
| 12/9/2021 | Merck | MRK | New Coverage | Overweight (N/A) |
72.28 (115.79) |
60.2% | Details | |
| 12/9/2021 | Pfizer | PFE | New Coverage | Overweight (N/A) |
51.72 (27.05) |
-47.7% | Details | |
| 12/9/2021 | Vertex | VRTX | New Coverage | Overweight (N/A) |
205.22 (456.69) |
122.54% | Details | |
| 12/9/2021 | Abbvie | ABBV | New Coverage | Overweight (N/A) |
121.51 (230.11) |
89.38% | Details |
